Sai Life Sciences has partnered with Agility Life Sciences and Centrix Pharma Solutions to launch an Integrated CMC Partnership. This collaboration aims to accelerate drug development for innovator biopharma companies by providing end-to-end services from API development to clinical manufacturing. The partnership combines the strengths of all three organizations, offering integrated drug substance and drug product development to improve efficiency from preclinical studies to clinical trials.
Strategic Collaboration for Drug Development
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions have announced the launch of an Integrated CMC Partnership, designed to expedite drug development for innovator biopharma companies. This collaboration integrates the strengths of each company to provide comprehensive Chemistry, Manufacturing, and Controls (CMC) services.
Comprehensive End-to-End Services
The partnership aims to offer end-to-end services, from API development to clinical manufacturing. This includes integrated drug substance and drug product development, helping clients move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond. Key benefits of the partnership include:
- Broad scientific expertise across multiple disciplines.
- End-to-end service coverage from synthetic route scouting to drug substance manufacturing.
- Cross-functional optimization: integrated planning across API and drug product development.
- Agility and flexibility to proactively respond to emerging technical risks.
- Seamless coordination between technical teams.
- Single point of contact from Day One.
Quotes from Leadership
Krishna Kanumuri, MD & CEO, Sai Life Sciences, stated, “We are delighted to partner with Agility Life Sciences and Centrix Pharma in this truly integrated CMC offering… By bringing together our complementary strengths, we can deliver far greater value to innovators.”
Dr Claire Thompson, CEO and Founder, Agility Life Sciences, commented, “Our combined expertise and energy will enable our clients’ molecules to be accelerated through key milestones, while reducing risk and cost.”
Chris Davison, CEO, Centrix Pharma Solutions, added, “What excites me most about this partnership is the spirit of collaboration it represents… At its heart, this is about people working side by side to turn promising science into medicines that can change lives.”
Source: BSE
